SCHEMBL777281

SCHEMBL777281

CCc1ccccc1OS(=O)(=O)Oc1ccccc1CC

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 3/20 0.50
MAPT P10636 2/20 0.50
NPSR1 Q6W5P4 1/20 0.50
DHODH Q02127 1/20 0.47
HPGD P15428 1/20 0.43
ATM Q13315 1/20 0.43
KDM4E B2RXH2 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
NISCH Q9Y2I1 1/20 0.39
CA12 O43570 1/20 0.39
CA1 P00915 1/20 0.39
CA2 P00918 1/20 0.39
CA5A P35218 1/20 0.39
CA9 Q16790 1/20 0.39
CA14 Q9ULX7 1/20 0.39
POLB P06746 1/20 0.39
HTT P42858 1/20 0.39
GABRA1 P14867 2/20 0.38
GABRB2 P47870 2/20 0.38
CTSB P07858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31714228 0.92 L3MBTL1 (0.47) L3MBTL1MAPTNPSR1DHODHHPGD
SCHEMBL7724402 0.86 CA12 (0.42) L3MBTL1MAPTNPSR1DHODHNISCH
SCHEMBL28967206 0.83 ELANE (0.55) L3MBTL1MAPTNPSR1DHODHHPGD
SCHEMBL777282 0.83 DHODH (0.48) L3MBTL1MAPTNPSR1DHODHHPGD
SCHEMBL16118575 0.83 CA2 (0.52) L3MBTL1MAPTNPSR1DHODHATM
Ammonia Solution, Strong SCHEMBL9821309 0.82 DHODH (0.47) L3MBTL1MAPTNPSR1DHODHHPGD
SCHEMBL11791849 0.81 THRA (0.52) CA1CA2CA9
SCHEMBL1822181 0.80 DHODH (0.59) L3MBTL1MAPTNPSR1DHODHSMN1; SMN2
SCHEMBL11654900 0.80 THRA (0.55)
SCHEMBL6838738 0.80 THRA (0.55)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 95 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240019417-A1 Methods and Systems for Determining Autism Spectrum Disorder Risk LABORATORY CORPORATION OF AMERICA HOLDINGS (US) 2024-01-18 US claimed
US-20220050090-A1 MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF MICROBIOTA RELATED METABOLITES METABOLON, INC. 2022-02-17 US claimed
EP-3850359-A1 MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF MICROBIOTA-RELATED METABOLITES Metabolon Inc. (US) 2021-07-21 EP claimed
WO-2020055631-A1 MASS SPECTROMETRY ASSAY METHOD FOR DETECTION AND QUANTITATION OF MICROBIOTA-RELATED METABOLITES METABOLON, INC. (US) 2020-03-19 WO claimed
US-20180235987-A1 GLYCAN COMPOSITIONS AND USES THEREOF HERCULES CAPITAL, INC. 2018-08-23 US claimed
EP-3071235-A1 GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF Kaleido Biosciences, Inc. (US) 2016-09-28 EP claimed
WO-2016122889-A1 GLYCAN THERAPEUTICS AND RELATED METHODS THEREOF KALEIDO BIOSCIENCES, INC. (US) 2016-08-04 WO claimed
US-5547806-A ADDING A DIALKYL SULFATE AND A POLYFUNCTIONAL ISOCYANATE COMPOUND; EMULSIFICATION; POLYMERIZATION; MICROENCAPSULATION FUJI PHOTO FILM CO., LTD. (JP) 1996-08-20 US claimed
US-20260034086-A1 Pet Food Compositions Comprising Caprylic Acid And Docosahexaenoic Acid And/Or Eicosapetaenoic Acid For Use In Treating Struvite Urolithiasis HILL'S PET NUTRITION, INC. (US) 2026-02-05 US disclosed
US-12458617-B2 Pet food compositions comprising caprylic acid and docosahexaenoic acid and/or eicosapetaenoic acid for use in treating struvite urolithiasis HILL'S PET NUTRITION, INC. (US) 2025-11-04 US disclosed
US-12377113-B2 Glycan therapeutic compositions and related methods thereof DSM NUTRITIONAL PRODUCTS, LLC (US) 2025-08-05 US disclosed
US-12100809-B2 Non-aqueous liquid electrolyte and non-aqueous liquid electrolyte secondary battery MITSUBISHI CHEMICAL CORPORATION (JP) 2024-09-24 US disclosed
US-20240108642-A1 GLYCAN THERAPEUTIC COMPOSITIONS AND RELATED METHODS THEREOF DSM NUTRITIONAL PRODUCTS, LLC 2024-04-04 US disclosed
US-11883422-B2 Glycan therapeutic compositions and related methods thereof DSM NUTRITIONAL PRODUCTS, LLC (US) 2024-01-30 US disclosed
EP-0410976-A4 HEAT STABLE QUATERNIZED LACTAMS HAVING OXYLATED SULFUR ANIONS 1991-10-16 EP disclosed
EP-0410976-A1 HEAT STABLE QUATERNIZED LACTAMS HAVING OXYLATED SULFUR ANIONS GAF CHEMICALS CORPORATION (US) 1991-02-06 EP disclosed
US-4957731-A CONDITIONERS, QUATERNIZED LACTAMS GAF CHEMICALS CORPORATION (US) 1990-09-18 US disclosed
US-4885158-A Heat stable quaternized lactams having oxylated sulfur anions GAF CORPORATION (US) 1989-12-05 US disclosed
WO-1989010115-A1 HAIR PROCESSING ADDITIVES GAF CHEMICALS CORPORATION (US) 1989-11-02 WO disclosed
WO-1989010358-A1 HEAT STABLE QUATERNIZED LACTAMS HAVING OXYLATED SULFUR ANIONS GAF CHEMICALS CORPORATION (US) 1989-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260034086-A1 Pet Food Compositions Comprising Caprylic Acid And Docosahexaenoic Acid And/Or Eicosapetaenoic Acid For Use In Treating Struvite Urolithiasis FPR2, FPR1, FPR3 L3MBTL1 3965/4885MAPT 2558/4885NPSR1 936/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.